Cargando…
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093591/ https://www.ncbi.nlm.nih.gov/pubmed/33947938 http://dx.doi.org/10.1038/s41375-021-01257-7 |
| _version_ | 1783687843007168512 |
|---|---|
| author | Grever, Michael Andritsos, Leslie Banerji, Versha Barrientos, Jacqueline C. Bhat, Seema Blachly, James S. Call, Timothy Cross, Matthew Dearden, Claire Demeter, Judit Dietrich, Sasha Falini, Brunangelo Forconi, Francesco Gladstone, Douglas E. Gozzetti, Alessandro Iyengar, Sunil Johnston, James B. Juliusson, Gunnar Kraut, Eric Kreitman, Robert J. Lauria, Francesco Lozanski, Gerard Parikh, Sameer A. Park, Jae Polliack, Aaron Ravandi, Farhad Robak, Tadeusz Rogers, Kerry A. Saven, Alan Seymour, John F. Tadmor, Tamar Tallman, Martin S. Tam, Constantine S. Tiacci, Enrico Troussard, Xavier Zent, Clive Zenz, Thorsten Zinzani, Pier Luigi Wörmann, Bernhard |
| author_facet | Grever, Michael Andritsos, Leslie Banerji, Versha Barrientos, Jacqueline C. Bhat, Seema Blachly, James S. Call, Timothy Cross, Matthew Dearden, Claire Demeter, Judit Dietrich, Sasha Falini, Brunangelo Forconi, Francesco Gladstone, Douglas E. Gozzetti, Alessandro Iyengar, Sunil Johnston, James B. Juliusson, Gunnar Kraut, Eric Kreitman, Robert J. Lauria, Francesco Lozanski, Gerard Parikh, Sameer A. Park, Jae Polliack, Aaron Ravandi, Farhad Robak, Tadeusz Rogers, Kerry A. Saven, Alan Seymour, John F. Tadmor, Tamar Tallman, Martin S. Tam, Constantine S. Tiacci, Enrico Troussard, Xavier Zent, Clive Zenz, Thorsten Zinzani, Pier Luigi Wörmann, Bernhard |
| author_sort | Grever, Michael |
| collection | PubMed |
| description | Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. |
| format | Online Article Text |
| id | pubmed-8093591 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80935912021-05-05 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines Grever, Michael Andritsos, Leslie Banerji, Versha Barrientos, Jacqueline C. Bhat, Seema Blachly, James S. Call, Timothy Cross, Matthew Dearden, Claire Demeter, Judit Dietrich, Sasha Falini, Brunangelo Forconi, Francesco Gladstone, Douglas E. Gozzetti, Alessandro Iyengar, Sunil Johnston, James B. Juliusson, Gunnar Kraut, Eric Kreitman, Robert J. Lauria, Francesco Lozanski, Gerard Parikh, Sameer A. Park, Jae Polliack, Aaron Ravandi, Farhad Robak, Tadeusz Rogers, Kerry A. Saven, Alan Seymour, John F. Tadmor, Tamar Tallman, Martin S. Tam, Constantine S. Tiacci, Enrico Troussard, Xavier Zent, Clive Zenz, Thorsten Zinzani, Pier Luigi Wörmann, Bernhard Leukemia Review Article Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. Nature Publishing Group UK 2021-05-04 2021 /pmc/articles/PMC8093591/ /pubmed/33947938 http://dx.doi.org/10.1038/s41375-021-01257-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Review Article Grever, Michael Andritsos, Leslie Banerji, Versha Barrientos, Jacqueline C. Bhat, Seema Blachly, James S. Call, Timothy Cross, Matthew Dearden, Claire Demeter, Judit Dietrich, Sasha Falini, Brunangelo Forconi, Francesco Gladstone, Douglas E. Gozzetti, Alessandro Iyengar, Sunil Johnston, James B. Juliusson, Gunnar Kraut, Eric Kreitman, Robert J. Lauria, Francesco Lozanski, Gerard Parikh, Sameer A. Park, Jae Polliack, Aaron Ravandi, Farhad Robak, Tadeusz Rogers, Kerry A. Saven, Alan Seymour, John F. Tadmor, Tamar Tallman, Martin S. Tam, Constantine S. Tiacci, Enrico Troussard, Xavier Zent, Clive Zenz, Thorsten Zinzani, Pier Luigi Wörmann, Bernhard Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title_full | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title_fullStr | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title_full_unstemmed | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title_short | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines |
| title_sort | hairy cell leukemia and covid-19 adaptation of treatment guidelines |
| topic | Review Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093591/ https://www.ncbi.nlm.nih.gov/pubmed/33947938 http://dx.doi.org/10.1038/s41375-021-01257-7 |
| work_keys_str_mv | AT grevermichael hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT andritsosleslie hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT banerjiversha hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT barrientosjacquelinec hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT bhatseema hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT blachlyjamess hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT calltimothy hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT crossmatthew hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT deardenclaire hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT demeterjudit hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT dietrichsasha hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT falinibrunangelo hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT forconifrancesco hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT gladstonedouglase hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT gozzettialessandro hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT iyengarsunil hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT johnstonjamesb hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT juliussongunnar hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT krauteric hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT kreitmanrobertj hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT lauriafrancesco hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT lozanskigerard hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT parikhsameera hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT parkjae hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT polliackaaron hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT ravandifarhad hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT robaktadeusz hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT rogerskerrya hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT savenalan hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT seymourjohnf hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT tadmortamar hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT tallmanmartins hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT tamconstantines hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT tiaccienrico hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT troussardxavier hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT zentclive hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT zenzthorsten hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT zinzanipierluigi hairycellleukemiaandcovid19adaptationoftreatmentguidelines AT wormannbernhard hairycellleukemiaandcovid19adaptationoftreatmentguidelines |